Payal Kohli, MD

Andexxa, CABANA, and new AF score. Cardiologist and Patient Care author Payal Kohli, MD, highlights 3 pivotal developments from 2018. 

From "Danger of sepsis" to "Birthday today," the EHR covers it all. Will a popup on prescribing anticoagulation catch on?

A 20-year observational study of nearly 7000 elite athletes found only 0.3% developed atrial fibrillation. Is it time to think differently?

Use of opioids in therapeutic doses in a large population of young veterans was linked to new-onset atrial fibrillation in a study reported at the AHA Scientific Sessions 2018.

A new study reveals the notable impact of the variation in published stroke rates on the net clinical benefit of anticoagulation in atrial fibrillation.

Results of a new study may prompt you to rethink how you approach anticoagulation for these 2 arrhythmias. Are they 1 entity, or 2?

The first study of its kind found ablation strategies used in normal hearts are safe, effective, and yield good results.

Brush up on your oral anticoagulation basics with answers to three key questions we posed to cardiologist and Patient Care board member Payal Kohli, MD.

Results of the CABANA study (atrial fibrillation) are up for evaluation. How did the trial work and could it change your thoughts on AF treatment?

And it's very good news for clinicians who routinely recite the pros/cons of direct oral anticoagulation to their patients with atrial fibrillation.  

Nuts have proven, once again, that they are one of the leading heart-healthy foods.

Post-procedure AF, once thought to be an artifact of healing, turns out to be a sign of significant risk, a new study finds.

The path to reducing risk of stroke in AF patients is far from straight and narrow. A case and 3 questions test your clinical navigation skills.

Consider this case of a 92-year-old man who presents with permanent atrial fibrillation and multiple comorbidities. Should he be anticoagulated?